Macitentan for the treatment of pulmonary arterial hypertension

Macitentan is the most recently approved dual endothelin-receptor antagonist (ERA) for the treatment of symptomatic pulmonary arterial hypertension. Compared to other available ERAs, it demonstrates superior receptor-binding properties, with consequently improved tissue penetration, and a longer dur...

Descripción completa

Detalles Bibliográficos
Autores principales: Kholdani, Cyrus A, Fares, Wassim H, Trow, Terence K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251661/
https://www.ncbi.nlm.nih.gov/pubmed/25473292
http://dx.doi.org/10.2147/VHRM.S33904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251661/
https://www.ncbi.nlm.nih.gov/pubmed/25473292
http://dx.doi.org/10.2147/VHRM.S33904

Ejemplares similares